FDA updates risk framework to curb antimicrobial resistance in food animals

The US Food and Drug Administration has finalised a revised framework for evaluating the human health risks of antimicrobial drugs in livestock, intensifying efforts to combat antimicrobial resistance.

The US Food and Drug Administration has finalised an updated framework for judging the human health risks posed by antimicrobial drugs used in food-producing animals, tightening a policy that sits at the centre of its work on antimicrobial resistance.

According to the agency, the revised Guidance for Industry 152 keeps its qualitative risk-assessment model but updates Appendix A, which sorts antimicrobial classes by their importance to human medicine. The categories remain critically important, highly important and important. The FDA said those rankings are designed to support risk assessment, not to function as a stand-alone control mechanism.

The guidance also expands hazard characterisation, refreshes risk-management language and explains why topical antimicrobials are excluded from the medical-importance list. The agency has long argued that excessive or inappropriate antimicrobial use can accelerate resistance, making infections harder to treat in both people and animals.

The finalisation follows a broader FDA campaign to promote stewardship in livestock medicine, including tighter controls on feed-use drugs, shifts from over-the-counter to prescription status, and assessments of resistance risk in the approval process. Covington reported that the revised GFI 152 replaces the 2003 version, although its basic purpose remains unchanged: to guide the agency’s review of animal drug applications involving medically important antimicrobials.